Protocol No.: EA9171

Title
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Principal Investigator
Ross, Kelly
Phase
II
Age Group
Adult
Applicable Disease Sites
Leukemia
Multiple Myeloma
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Vicky Lynn, RN
Research Nurse
Phone: +1 304-293-8407

View on ClinicalTrials.gov